Home > Insider Trading > Filing (0001140361-14-040632)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184149	W Jonathan Ayers	One Idexx Drive Westbrook ME 04092	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-11-05	29,000	$28.66	445,081	No	4	M	Direct
Common Stock	Disposition	2014-11-05	12,918	$142.76	432,163	No	4	S	Direct
Common Stock	Disposition	2014-11-05	9,895	$143.72	422,268	No	4	S	Direct
Common Stock	Disposition	2014-11-05	6,187	$144.47	416,081	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2014-11-05	29,000	$0.00	29,000	$28.66

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
57,512		2015-02-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	49,000	Indirect	By Ayers Family Trust

Footnotes

Includes 45 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2014.
The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $142.20 to 143.19, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4 and 5 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $143.20 to $144.13, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $144.21 to $144.64, inclusive.
Grant of options to buy shares of common stock that became exercisable as to 20,000 shares on 02/03/2006, 02/03/2007, 02/03/2008 and 02/03/2009, and the remaining 16,512 shares on 02/03/2010.